Amneal Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Amneal Pharmaceuticals has a total shareholder equity of $61.3M and total debt of $2.6B, which brings its debt-to-equity ratio to 4307.3%. Its total assets and total liabilities are $3.5B and $3.4B respectively. Amneal Pharmaceuticals's EBIT is $271.4M making its interest coverage ratio 1.3. It has cash and short-term investments of $93.7M.
Key information
4,307.3%
Debt to equity ratio
US$2.64b
Debt
Interest coverage ratio | 1.3x |
Cash | US$93.74m |
Equity | US$61.30m |
Total liabilities | US$3.41b |
Total assets | US$3.47b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2DT's short term assets ($1.4B) exceed its short term liabilities ($846.6M).
Long Term Liabilities: 2DT's short term assets ($1.4B) do not cover its long term liabilities ($2.6B).
Debt to Equity History and Analysis
Debt Level: 2DT's net debt to equity ratio (4154.4%) is considered high.
Reducing Debt: 2DT's debt to equity ratio has increased from 295.9% to 4307.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 2DT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 2DT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 9.6% per year.